Treatment outcomes of tuberculosis (TB) patients with rifampin (RMP) or RMP and isoniazid (INH) resistance receiving standard regimen Source: Eur Respir J 2003; 22: Suppl. 45, 42s Year: 2003
Tolerance to rifampicine (RIF) 4 months vs. isoniazid (INH) 6 months for latent tuberculosis infection (LTBI) Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis Year: 2008
Latent tuberculosis (infection). Evaluation of a short course treatment with isoniazid, rifampin and pyrazinamid Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
Multi drug resistant (rifampicin + isoniazid) pulmonary tuberculosis – a challenge for a developing country specially co-infected with HIV Source: Eur Respir J 2007; 30: Suppl. 51, 421s Year: 2007
Extensively drug resistant tuberculosis (XDR TB) in a high income country: a report of four unrelated cases Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007
Long term plasma rifampicin (R) concentrations in AIDS patients with tuberculosis (TB) under HAART therapy Source: Eur Respir J 2003; 22: Suppl. 45, 40s Year: 2003
Two months isoniazid, rifampin and pirazinamid for latent tuberculosis infection Source: Annual Congress 2010 - Special treatment options in tuberculosis Year: 2010
Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005
Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs Source: Eur Respir J, 55 (3) 1902048; 10.1183/13993003.02048-2019 Year: 2020
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013
Tuberculosis (TB) relapse rate among patients treated with moxifloxacin (m) or ethambutol (E) in the intensive phase of therapy Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Primary multidrug resistance (PMDR) of mycobacterium tuberculosis (MBT) to antimycobacterial drugs (AMBTD) in the patients with destructive TB. Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
What is latent tuberculosis infection (LTBI)? Source: Annual Congress 2009 - Microbial colonisation or latency: a foot in the door to respiratory infections Year: 2009
Primary resistance (PR) of mycobacterium tuberculosis (MBT) to antimicrobial drugs (AMBD) in patients (P) with destructive pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 655s Year: 2004
Multi-drug resistant tuberculosis (MDR-TB) in Ramnicul Valcear, Romania; drug treatment, resistance testing and adverse drug reactions Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006
Surgical treatment of destructive pulmonary tuberculosis (TB) with multi-drug resistance (MDR) Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009
The role of quantiferon tuberculosis gold test (Q) in diagnosing active tuberculosis (TB) and latent tuberculosis infection (LTI) in children Source: Annual Congress 2008 - New tests and methods to diagnose tuberculosis infection and disease and to monitor treatment Year: 2008
High completion rates with directly observed preventive treatment (DOPT) of latent tuberculosis infection (LTBI) in Ethiopian immigrants (EI) to Israel Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I Year: 2012